Christopher N Ta, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ta’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A54687 · Current
Licensed to practise in California · since 1995 · expires 2027-07-31 · University of Minnesota Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$89,864
Medicare paid this office $89,864 for 372 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 249 | $45,595 | $82 |
| Long return visit (40+ min) | 113 | $18,002 | $118 |
| Closure of tear duct opening using plug | 34 | $11,411 | $91 |
| Short return visit (20+ min) | 76 | $5,493 | $52 |
| New patient visit (45+ min) | 24 | $2,411 | $100 |
See all 12 services
| Return visit (30+ min) | 249 | $45,595 | $82 |
| Long return visit (40+ min) | 113 | $18,002 | $118 |
| Closure of tear duct opening using plug | 34 | $11,411 | $91 |
| Short return visit (20+ min) | 76 | $5,493 | $52 |
| New patient visit (45+ min) | 24 | $2,411 | $100 |
| Scraping of cornea for diagnosis | 14 | $1,063 | $76 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 51 | $1,004 | $15 |
| Established patient complete exam of visual system | 14 | $771 | $55 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 15 | $590 | $27 |
| Exam of visual field with extended testing | 23 | $574 | $23 |
| Removal of eyelashes using forceps | 15 | $546 | $21 |
| Imaging of front third of eye using a special microscope | 21 | $437 | $19 |
Who their Medicare patients are
372 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 14% · Women 70% · Also on Medicaid 28% · Health risk score 1.59. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 67% · Diabetes 24% · Coronary heart disease 24% · Chronic kidney disease 17% · Depression 16% · Atrial fibrillation 15% · Cancer 14% · COPD 13% · Heart failure 12% · Stroke 9% · Dementia 6%.
The office billed $254,619, Medicare allowed $122,041 and paid $89,864; for 1,210 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 372 | 1,210 | 75 | 1.59 | $254,619 | $89,864 |
| 2023 | 387 | 1,428 | 75 | 1.55 | $307,666 | $118,045 |
| 2022 | 370 | 1,185 | 74 | 1.57 | $243,193 | $88,163 |
| 2021 | 367 | 1,221 | 74 | 1.65 | $224,365 | $92,674 |
| 2020 | 358 | 1,171 | 74 | 1.72 | $200,014 | $74,959 |
| 2019 | 377 | 1,259 | 73 | 1.68 | $280,572 | $82,017 |
| 2018 | 395 | 1,628 | 73 | 1.56 | $494,095 | $109,314 |
| 2017 | 402 | 1,401 | 73 | 1.48 | $420,552 | $85,890 |
| 2016 | 410 | 1,593 | 73 | 1.56 | $526,385 | $97,540 |
| 2015 | 373 | 1,329 | 73 | 1.38 | $473,897 | $85,454 |
| 2014 | 441 | 1,741 | 74 | 1.34 | $507,940 | $101,032 |
| 2013 | 396 | 1,772 | 74 | 1.40 | $778,295 | $128,329 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Return visit (30+ min) | 248 | $46,650 | $84 |
| Long return visit (40+ min) | 141 | $36,018 | $127 |
| Closure of tear duct opening using plug | 37 | $11,990 | $92 |
| Short return visit (20+ min) | 74 | $5,199 | $54 |
| New patient visit (45+ min) | 33 | $3,565 | $108 |
| Scraping of cornea for diagnosis | 25 | $3,198 | $97 |
| New patient visit (60+ min) | 18 | $2,589 | $144 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 32 | $1,828 | $28 |
| Established patient complete exam of visual system | 21 | $1,216 | $58 |
| 2d ultrasound scan of eye tissue and structures | 19 | $1,031 | $28 |
| Removal of eyelashes using forceps | 22 | $877 | $23 |
| Exam of visual field with extended testing | 18 | $452 | $23 |
| Imaging of front third of eye using a special microscope | 19 | $410 | $20 |
| Photography of content of eyes | 16 | $47 | $3 |
2022: 12 services
| Return visit (30+ min) | 226 | $39,853 | $81 |
| Long return visit (40+ min) | 73 | $14,095 | $117 |
| Closure of tear duct opening using plug | 45 | $12,657 | $112 |
| Short return visit (20+ min) | 115 | $8,128 | $49 |
| Established patient complete exam of visual system | 65 | $4,326 | $65 |
| New patient visit (45+ min) | 25 | $2,371 | $95 |
| Scraping of cornea for diagnosis | 13 | $1,393 | $93 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $1,053 | $29 |
| Removal of eyelashes using forceps | 11 | $662 | $25 |
| Imaging of front third of eye using a special microscope | 29 | $648 | $19 |
| Exam of visual field with extended testing | 15 | $307 | $20 |
| Photography of content of eyes | 20 | $58 | $3 |
2021: 11 services
| Return visit (30+ min) | 226 | $43,372 | $83 |
| Closure of tear duct opening using plug | 37 | $12,713 | $94 |
| Long return visit (40+ min) | 78 | $12,090 | $119 |
| Short return visit (20+ min) | 124 | $8,919 | $55 |
| Established patient complete exam of visual system | 60 | $4,102 | $68 |
| New patient visit (45+ min) | 32 | $3,539 | $111 |
| Scraping of cornea for diagnosis | 17 | $2,187 | $95 |
| Imaging of front third of eye using a special microscope | 27 | $569 | $19 |
| Removal of eyelashes using forceps | 11 | $494 | $25 |
| Exam of visual field with extended testing | 14 | $392 | $26 |
| Photography of content of eyes | 31 | $102 | $3 |
2020: 12 services
| Return visit (30+ min) | 181 | $21,242 | $67 |
| Long return visit (40+ min) | 140 | $18,938 | $98 |
| Closure of tear duct opening using plug | 38 | $11,362 | $82 |
| Short return visit (20+ min) | 146 | $9,875 | $42 |
| New patient visit (45+ min) | 33 | $3,543 | $107 |
| Scraping of cornea for diagnosis | 17 | $2,263 | $98 |
| Established patient complete exam of visual system | 29 | $1,693 | $58 |
| Imaging of front third of eye using a special microscope | 39 | $777 | $18 |
| 2d ultrasound scan of eye tissue and structures | 14 | $649 | $30 |
| Exam of visual field with extended testing | 11 | $269 | $24 |
| Ct scan of cornea | 13 | $173 | $12 |
| Photography of content of eyes | 30 | $104 | $3 |
2019: 14 services
| Return visit (30+ min) | 177 | $21,152 | $66 |
| Long return visit (40+ min) | 122 | $14,571 | $89 |
| Closure of tear duct opening using plug | 39 | $10,697 | $84 |
| Short return visit (20+ min) | 143 | $10,096 | $44 |
| New patient visit (45+ min) | 34 | $3,635 | $107 |
| Established patient complete exam of visual system | 39 | $2,628 | $66 |
| Scraping of cornea for diagnosis | 19 | $2,342 | $84 |
| 2d ultrasound scan of eye tissue and structures | 22 | $1,082 | $33 |
| Removal of eyelashes using forceps | 11 | $1,049 | $35 |
| Imaging of front third of eye using a special microscope | 40 | $990 | $19 |
| New patient visit (30+ min) | 11 | $617 | $56 |
| Exam of visual field with extended testing | 16 | $398 | $22 |
| Ct scan of cornea | 16 | $325 | $15 |
| Photography of content of eyes | 62 | $187 | $2 |
2018: 16 services
| Return visit (30+ min) | 207 | $25,155 | $65 |
| Long return visit (40+ min) | 177 | $25,081 | $93 |
| Closure of tear duct opening using plug | 47 | $14,054 | $83 |
| Short return visit (20+ min) | 143 | $9,429 | $41 |
| Scraping of cornea for diagnosis | 24 | $3,645 | $91 |
| New patient visit (45+ min) | 33 | $3,293 | $100 |
| 2d ultrasound scan of eye tissue and structures | 25 | $1,465 | $40 |
| Removal of eyelashes using forceps | 14 | $1,146 | $46 |
| Established patient complete exam of visual system | 18 | $1,128 | $63 |
| Imaging of retina | 40 | $958 | $23 |
| Imaging of front third of eye using a special microscope | 48 | $892 | $18 |
| Exam of visual field with extended testing | 17 | $522 | $26 |
| Ct scan of cornea | 27 | $507 | $18 |
| Imaging of front third of eye | 23 | $369 | $13 |
| Photography of content of eyes | 101 | $353 | $3 |
| Photography of the retina | 14 | $265 | $19 |
2017: 13 services
| Return visit (30+ min) | 202 | $23,676 | $65 |
| Long return visit (40+ min) | 131 | $13,760 | $88 |
| Short return visit (20+ min) | 158 | $10,564 | $40 |
| Closure of tear duct opening using plug | 24 | $6,408 | $81 |
| New patient visit (45+ min) | 51 | $5,182 | $102 |
| Scraping of cornea for diagnosis | 21 | $3,435 | $93 |
| 2d ultrasound scan of eye tissue and structures | 13 | $1,492 | $47 |
| Imaging of front third of eye using a special microscope | 75 | $1,487 | $18 |
| Established patient complete exam of visual system | 16 | $921 | $58 |
| Ct scan of cornea | 31 | $489 | $16 |
| Imaging of retina | 18 | $410 | $23 |
| Photography of content of eyes | 101 | $297 | $2 |
| Exam of visual field with extended testing | 11 | $260 | $20 |
2016: 18 services
| Return visit (30+ min) | 199 | $23,722 | $65 |
| Long return visit (40+ min) | 138 | $16,799 | $89 |
| Short return visit (20+ min) | 173 | $10,812 | $40 |
| Closure of tear duct opening using plug | 36 | $8,936 | $84 |
| New patient visit (45+ min) | 62 | $6,385 | $103 |
| Scraping of cornea for diagnosis | 25 | $2,199 | $76 |
| 2d ultrasound scan of eye tissue and structures | 28 | $2,069 | $47 |
| Closure of tear duct opening using plug | 12 | $1,636 | $91 |
| New patient visit (60+ min) | 11 | $1,614 | $147 |
| Established patient complete exam of visual system | 24 | $1,554 | $62 |
| Imaging of front third of eye using a special microscope | 70 | $1,446 | $20 |
| Imaging of retina | 34 | $867 | $25 |
| Fitting of contact lens for treatment of eye surface disease | 11 | $650 | $28 |
| Ct scan of cornea | 30 | $510 | $17 |
| Exam of visual field with extended testing | 18 | $467 | $23 |
| Photography of content of eyes | 102 | $404 | $3 |
| Imaging of front third of eye | 20 | $395 | $16 |
| Photography of the retina | 21 | $386 | $18 |
2015: 12 services
| Return visit (30+ min) | 195 | $17,972 | $63 |
| Long return visit (40+ min) | 117 | $13,669 | $90 |
| Short return visit (20+ min) | 148 | $10,603 | $40 |
| Closure of tear duct opening using plug | 23 | $5,488 | $82 |
| New patient visit (45+ min) | 54 | $5,390 | $100 |
| Established patient complete exam of visual system | 32 | $2,090 | $65 |
| 2d ultrasound scan of eye tissue and structures | 20 | $1,688 | $44 |
| Imaging of front third of eye using a special microscope | 75 | $1,478 | $18 |
| Imaging of retina | 55 | $1,443 | $25 |
| Ct scan of cornea | 37 | $788 | $18 |
| Photography of the retina | 15 | $319 | $21 |
| Photography of content of eyes | 86 | $256 | $3 |
2014: 15 services
| Return visit (30+ min) | 228 | $25,442 | $66 |
| Short return visit (20+ min) | 182 | $15,379 | $42 |
| Long return visit (40+ min) | 127 | $14,098 | $94 |
| Closure of tear duct opening using plug | 41 | $9,175 | $84 |
| New patient visit (45+ min) | 80 | $8,487 | $106 |
| 2d ultrasound scan of eye tissue and structures | 24 | $2,360 | $49 |
| Imaging of front third of eye using a special microscope | 107 | $2,265 | $20 |
| Imaging of retina | 78 | $2,158 | $26 |
| Scraping of cornea for diagnosis | 11 | $1,239 | $88 |
| Established patient complete exam of visual system | 20 | $1,119 | $53 |
| Ct scan of cornea | 53 | $1,067 | $18 |
| New patient visit (30+ min) | 14 | $630 | $45 |
| Photography of content of eyes | 123 | $398 | $3 |
| Exam of visual field with extended testing | 12 | $314 | $26 |
| Ultrasound scan of cornea to determine thickness | 27 | $254 | $8 |
2013: 18 services
| Return visit (30+ min) | 220 | $24,851 | $62 |
| Short return visit (20+ min) | 182 | $15,626 | $41 |
| Long return visit (40+ min) | 100 | $10,612 | $88 |
| Closure of tear duct opening using plug | 43 | $10,013 | $83 |
| Removal of growth of cornea | 12 | $6,648 | $554 |
| New patient visit (45+ min) | 60 | $6,262 | $104 |
| 2d ultrasound scan of eye tissue and structures | 47 | $4,253 | $49 |
| Scraping of cornea for diagnosis | 24 | $3,190 | $89 |
| Imaging of front third of eye using a special microscope | 79 | $1,546 | $19 |
| New patient visit (30+ min) | 25 | $1,522 | $61 |
| Established patient complete exam of visual system | 19 | $1,228 | $65 |
| Fitting of contact lens for treatment of eye surface disease | 20 | $944 | $26 |
| Imaging of retina | 19 | $498 | $26 |
| Ct scan of cornea | 24 | $479 | $18 |
| Exam of visual field with extended testing | 18 | $434 | $23 |
| Photography of content of eyes | 116 | $374 | $3 |
| Exam of the internal drainage system of eye | 20 | $329 | $16 |
| Ultrasound scan of cornea to determine thickness | 26 | $223 | $8 |
Medicaid work
$6,644 in 2024
Medicaid paid $6,644 for 151 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 137 | $6,058 |
| Long return visit (40+ min) | 14 | $586 |
| 2024 | 151 | 2 | 21 | $6,644 |
| 2023 | 408 | 2 | 28 | $13,907 |
| 2022 | 238 | 1 | 23 | $8,327 |
| 2021 | 208 | 1 | 22 | $6,972 |
| 2020 | 20 | 1 | 18 | $762 |
| 2019 | 78 | 3 | 17 | $1,880 |
| 2018 | 152 | 2 | 24 | $5,154 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 302 | $9,512 |
| Long return visit (40+ min) | 106 | $4,395 |
2022
| Return visit (30+ min) | 238 | $8,327 |
2021
| Return visit (30+ min) | 208 | $6,972 |
2020
| Return visit (30+ min) | 20 | $762 |
2019
| Long return visit (40+ min) | 32 | $925 |
| Return visit (30+ min) | 33 | $755 |
| Short return visit (20+ min) | 13 | $200 |
2018
| Return visit (30+ min) | 96 | $2,677 |
| Long return visit (40+ min) | 56 | $2,477 |
Drugs they prescribed that Part D paid
$263,370
Pharmacies billed $263,370 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 888) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
570 generic and 318 brand-name prescriptions · $263,370 in drug cost · 114 antibiotic prescriptions to 32 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 91 | $114,934 | $1,263 |
| Xiidra | 62 | $66,790 | $1,077 |
| Cyclosporine | 51 | $25,873 | $507 |
| Miebo | 22 | $17,839 | $811 |
| Valacyclovir | 71 | $5,011 | $71 |
See all 12 drugs
| Restasis | 91 | $114,934 | $1,263 |
| Xiidra | 62 | $66,790 | $1,077 |
| Cyclosporine | 51 | $25,873 | $507 |
| Miebo | 22 | $17,839 | $811 |
| Valacyclovir | 71 | $5,011 | $71 |
| Doxycycline Hyclate | 106 | $3,572 | $34 |
| Moxifloxacin | 78 | $2,396 | $31 |
| Prednisolone Acetate | 52 | $1,853 | $36 |
| Erythromycin | 186 | $1,647 | $9 |
| Acyclovir | 19 | $402 | $21 |
| Azithromycin | 14 | $143 | $10 |
| Polymyxin B Sul-Trimethoprim | 14 | $97 | $7 |
Year by year
| 2024 | 888 | 247 | 0% (0) | 36% | $263,370 |
| 2023 | 1,035 | 253 | 0% (0) | 34% | $839,990 |
| 2022 | 1,034 | 248 | 0% (0) | 36% | $812,150 |
| 2021 | 1,026 | 251 | 0% (0) | 38% | $816,586 |
| 2020 | 1,104 | 239 | 0% (0) | 43% | $1,148,494 |
| 2019 | 1,083 | 236 | 0% (0) | 52% | $868,912 |
| 2018 | 1,283 | 253 | 0% (0) | 51% | $338,283 |
| 2017 | 1,258 | 256 | 0% (0) | 54% | $263,337 |
| 2016 | 1,230 | 261 | None | 58% | $207,174 |
| 2015 | 1,358 | 235 | None | 60% | $181,467 |
| 2014 | 1,371 | 264 | None | 61% | $172,208 |
| 2013 | 1,454 | 228 | None | 58% | $146,528 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Oxervate | 20 | $498,034 | $24,902 |
| Restasis | 117 | $175,801 | $1,503 |
| Xiidra | 50 | $68,480 | $1,370 |
| Cyclosporine | 44 | $43,395 | $986 |
| Valacyclovir | 88 | $9,997 | $114 |
| Doxycycline Hyclate | 145 | $6,149 | $42 |
| Moxifloxacin | 109 | $4,617 | $42 |
| Prednisolone Acetate | 70 | $2,922 | $42 |
| Acyclovir | 25 | $2,225 | $89 |
| Erythromycin | 154 | $1,634 | $11 |
| Bacitracin | 12 | $1,259 | $105 |
| Fluorometholone | 11 | $716 | $65 |
| Azithromycin | 15 | $498 | $33 |
| Azelastine | 18 | $480 | $27 |
| Famciclovir | 14 | $434 | $31 |
| Doxycycline Monohydrate | 14 | $371 | $26 |
| Timolol Maleate | 18 | $181 | $10 |
2022: 18 drugs
| Oxervate | 18 | $474,973 | $26,387 |
| Restasis | 124 | $173,783 | $1,401 |
| Xiidra | 75 | $83,255 | $1,110 |
| Valacyclovir | 95 | $10,049 | $106 |
| Doxycycline Hyclate | 162 | $8,023 | $50 |
| Moxifloxacin | 63 | $3,398 | $54 |
| Prednisolone Acetate | 55 | $2,656 | $48 |
| Loteprednol Etabonate | 13 | $2,543 | $196 |
| Erythromycin | 172 | $1,685 | $10 |
| Olopatadine | 12 | $1,432 | $119 |
| Fluorometholone | 14 | $901 | $64 |
| Latanoprost | 26 | $536 | $21 |
| Acyclovir | 19 | $497 | $26 |
| Doxycycline Monohydrate | 16 | $331 | $21 |
| Azithromycin | 15 | $293 | $20 |
| Timolol Maleate | 19 | $205 | $11 |
| Azelastine | 11 | $98 | $9 |
| Famciclovir | 12 | $97 | $8 |
2021: 16 drugs
| Restasis | 129 | $181,427 | $1,406 |
| Xiidra | 97 | $83,801 | $864 |
| Lotemax | 24 | $7,739 | $322 |
| Doxycycline Hyclate | 111 | $7,733 | $70 |
| Valacyclovir | 85 | $5,790 | $68 |
| Olopatadine | 81 | $5,175 | $64 |
| Loteprednol Etabonate | 22 | $4,409 | $200 |
| Prednisolone Acetate | 46 | $2,707 | $59 |
| Erythromycin | 174 | $1,951 | $11 |
| Moxifloxacin | 33 | $1,603 | $49 |
| Azelastine | 21 | $1,142 | $54 |
| Famciclovir | 13 | $960 | $74 |
| Acyclovir | 38 | $833 | $22 |
| Latanoprost | 12 | $389 | $32 |
| Azithromycin | 18 | $300 | $17 |
| Timolol Maleate | 22 | $155 | $7 |
2020: 17 drugs
| Oxervate | 25 | $829,061 | $33,162 |
| Restasis | 124 | $170,348 | $1,374 |
| Xiidra | 131 | $88,568 | $676 |
| Lotemax | 48 | $12,403 | $258 |
| Olopatadine | 155 | $7,090 | $46 |
| Doxycycline Hyclate | 98 | $6,569 | $67 |
| Valacyclovir | 101 | $6,291 | $62 |
| Loteprednol Etabonate | 16 | $3,702 | $231 |
| Prednisolone Acetate | 59 | $2,793 | $47 |
| Brimonidine | 11 | $2,682 | $244 |
| Moxifloxacin | 53 | $2,374 | $45 |
| Erythromycin | 126 | $1,540 | $12 |
| Bacitracin | 15 | $1,333 | $89 |
| Acyclovir | 30 | $793 | $26 |
| Timolol Maleate | 25 | $227 | $9 |
| Acetylcysteine | 11 | $97 | $9 |
| Azithromycin | 11 | $78 | $7 |
2019: 16 drugs
| Oxervate | 32 | $584,746 | $18,273 |
| Restasis | 117 | $139,934 | $1,196 |
| Xiidra | 124 | $72,477 | $584 |
| Lotemax | 64 | $18,517 | $289 |
| Olopatadine | 113 | $8,822 | $78 |
| Valacyclovir | 122 | $6,033 | $49 |
| Doxycycline Hyclate | 83 | $4,629 | $56 |
| Moxifloxacin | 73 | $4,085 | $56 |
| Prednisolone Acetate | 71 | $3,609 | $51 |
| Simbrinza | 12 | $3,367 | $281 |
| Pazeo | 15 | $3,060 | $204 |
| Acyclovir | 39 | $973 | $25 |
| Erythromycin | 55 | $733 | $13 |
| Latanoprost | 12 | $295 | $25 |
| Timolol Maleate | 26 | $240 | $9 |
| Polymyxin B Sul-Trimethoprim | 17 | $152 | $9 |
2018: 19 drugs
| Restasis | 172 | $170,884 | $994 |
| Xiidra | 111 | $67,791 | $611 |
| Lotemax | 105 | $26,136 | $249 |
| Restasis Multidose | 13 | $12,145 | $934 |
| Valacyclovir | 138 | $9,146 | $66 |
| Olopatadine | 97 | $7,806 | $80 |
| Doxycycline Hyclate | 117 | $5,626 | $48 |
| Prednisolone Acetate | 77 | $4,631 | $60 |
| Moxifloxacin | 57 | $3,777 | $66 |
| Zioptan | 12 | $2,909 | $242 |
| Besivance | 11 | $1,774 | $161 |
| Fluorometholone | 17 | $1,122 | $66 |
| Acyclovir | 55 | $1,115 | $20 |
| Bacitracin | 11 | $911 | $83 |
| Erythromycin | 74 | $840 | $11 |
| Latanoprost | 32 | $566 | $18 |
| Sulfacetamide | 19 | $353 | $19 |
| Timolol Maleate | 22 | $217 | $10 |
| Polymyxin B Sul-Trimethoprim | 16 | $154 | $10 |
2017: 18 drugs
| Restasis | 138 | $112,947 | $818 |
| Xiidra | 74 | $39,363 | $532 |
| Lotemax | 91 | $22,146 | $243 |
| Pataday | 54 | $9,142 | $169 |
| Vigamox | 37 | $6,950 | $188 |
| Doxycycline Hyclate | 84 | $6,079 | $72 |
| Prednisolone Acetate | 94 | $5,907 | $63 |
| Valacyclovir | 94 | $5,905 | $63 |
| Azasite | 19 | $3,348 | $176 |
| Olopatadine | 31 | $3,023 | $98 |
| Pazeo | 11 | $2,841 | $258 |
| Fluorometholone | 21 | $1,465 | $70 |
| Moxifloxacin | 18 | $1,403 | $78 |
| Acyclovir | 76 | $1,378 | $18 |
| Erythromycin | 104 | $1,232 | $12 |
| Latanoprost | 46 | $755 | $16 |
| Timolol Maleate | 41 | $349 | $9 |
| Polymyxin B Sul-Trimethoprim | 21 | $187 | $9 |
2016: 19 drugs
| Restasis | 150 | $91,046 | $607 |
| Lotemax | 76 | $17,237 | $227 |
| Vigamox | 62 | $11,542 | $186 |
| Prednisolone Acetate | 140 | $8,348 | $60 |
| Pataday | 48 | $7,750 | $161 |
| Valacyclovir | 90 | $6,465 | $72 |
| Doxycycline Hyclate | 64 | $5,006 | $78 |
| Azasite | 20 | $3,703 | $185 |
| Combigan | 14 | $3,543 | $253 |
| Durezol | 18 | $3,324 | $185 |
| Lastacaft | 17 | $3,055 | $180 |
| Zioptan | 13 | $2,474 | $190 |
| Fluorometholone | 23 | $1,761 | $77 |
| Acyclovir | 80 | $1,538 | $19 |
| Besivance | 11 | $1,470 | $134 |
| Olopatadine | 18 | $1,244 | $69 |
| Erythromycin | 100 | $1,237 | $12 |
| Latanoprost | 42 | $566 | $13 |
| Timolol Maleate | 48 | $535 | $11 |
2015: 24 drugs
| Restasis | 163 | $69,264 | $425 |
| Lotemax | 99 | $20,599 | $208 |
| Prednisolone Acetate | 183 | $12,494 | $68 |
| Vigamox | 63 | $8,999 | $143 |
| Pataday | 46 | $7,216 | $157 |
| Timoptic Ocudose | 14 | $5,311 | $379 |
| Durezol | 35 | $5,279 | $151 |
| Valacyclovir | 65 | $5,118 | $79 |
| Doxycycline Hyclate | 58 | $4,909 | $85 |
| Azasite | 30 | $4,124 | $137 |
| Lastacaft | 23 | $3,622 | $157 |
| Combigan | 16 | $3,139 | $196 |
| Patanol | 12 | $3,125 | $260 |
| Acyclovir | 89 | $1,881 | $21 |
| Zioptan | 13 | $1,822 | $140 |
| Simbrinza | 14 | $1,649 | $118 |
| Erythromycin | 102 | $1,390 | $14 |
| Fluorometholone | 19 | $1,213 | $64 |
| Bacitracin | 21 | $1,171 | $56 |
| Latanoprost | 42 | $528 | $13 |
| Doxycycline Monohydrate | 16 | $487 | $30 |
| Timolol Maleate | 62 | $479 | $8 |
| Ofloxacin | 14 | $255 | $18 |
| Polymyxin B Sul-Trimethoprim | 16 | $129 | $8 |
2014: 24 drugs
| Restasis | 134 | $48,000 | $358 |
| Lotemax | 125 | $25,026 | $200 |
| Prednisolone Acetate | 230 | $16,407 | $71 |
| Valacyclovir | 84 | $9,553 | $114 |
| Vigamox | 47 | $6,458 | $137 |
| Patanol | 34 | $6,401 | $188 |
| Pataday | 35 | $4,932 | $141 |
| Besivance | 38 | $4,724 | $124 |
| Doxycycline Hyclate | 41 | $4,243 | $103 |
| Combigan | 29 | $3,945 | $136 |
| Intron A | 11 | $3,146 | $286 |
| Lastacaft | 22 | $2,889 | $131 |
| Azasite | 13 | $2,730 | $210 |
| Famciclovir | 14 | $1,966 | $140 |
| Brimonidine | 11 | $1,721 | $156 |
| Acyclovir | 82 | $1,669 | $20 |
| Bacitracin | 24 | $1,513 | $63 |
| Erythromycin | 78 | $1,100 | $14 |
| Fluorometholone | 13 | $655 | $50 |
| Latanoprost | 45 | $652 | $14 |
| Timolol Maleate | 53 | $509 | $10 |
| Sulfacetamide | 13 | $310 | $24 |
| Azithromycin | 13 | $277 | $21 |
| Polymyxin B Sul-Trimethoprim | 22 | $214 | $10 |
2013: 27 drugs
| Restasis | 138 | $44,231 | $321 |
| Valacyclovir | 139 | $15,316 | $110 |
| Lotemax | 62 | $10,071 | $162 |
| Prednisolone Acetate | 238 | $7,733 | $32 |
| Vigamox | 72 | $7,580 | $105 |
| Patanol | 36 | $5,595 | $155 |
| Pataday | 39 | $4,986 | $128 |
| Besivance | 42 | $4,636 | $110 |
| Natacyn | 15 | $3,807 | $254 |
| Doxycycline Hyclate | 35 | $2,755 | $79 |
| Intron A | 13 | $2,694 | $207 |
| Alphagan P | 14 | $2,461 | $176 |
| Lastacaft | 17 | $2,438 | $143 |
| Combigan | 23 | $2,404 | $105 |
| Durezol | 14 | $2,094 | $150 |
| Azasite | 12 | $2,048 | $171 |
| Acyclovir | 82 | $1,783 | $22 |
| Doxycycline Monohydrate | 27 | $1,612 | $60 |
| Betimol | 20 | $1,356 | $68 |
| Famciclovir | 14 | $1,306 | $93 |
| Bacitracin | 18 | $1,236 | $69 |
| Latanoprost | 41 | $900 | $22 |
| Timolol Maleate | 78 | $664 | $9 |
| Polymyxin B Sul-Trimethoprim | 53 | $596 | $11 |
| Erythromycin | 30 | $470 | $16 |
| Bacitracin-Polymyxin | 20 | $441 | $22 |
| Ofloxacin | 13 | $157 | $12 |
Money from drug and device companies
$2,441 in 2025
| 2025 | 2 | 3 | $2,400 | $2,441 |
| 2024 | 3 | 4 | None | $428 |
| 2023 | 3 | 5 | None | $531 |
| 2022 | 7 | 10 | $5,075 | $5,526 |
| 2021 | 4 | 7 | None | $722 |
| 2020 | 2 | 2 | $1,680 | $1,715 |
| 2019 | 4 | 11 | $6,525 | $6,955 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Dompe Farmaceutici S.p.A. | None | $2,410 | 2 payments
|
| Alcon Vision | Clareon | $31 | 1 payment
|
See all 3 published payments
| Dompe Farmaceutici S.p.A. | Consulting · 2025-12-22 | None | $2,400 |
| Dompe Farmaceutici S.p.A. | Meals · 2025-10-17 | None | $10 |
| Alcon Vision | Meals · 2025-05-21 | Clareon | $31 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $428
| Alcon Vision | Argos | $237 | 2 payments
|
| Oyster Point Pharma | Tyrvaya | $108 | 1 payment
|
| Dompe US | Oxervate | $83 | 1 payment
|
2023: $531
| Alcon Vision | Clareon | $386 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $100 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $45 | 1 payment
|
2022: $5,526
| Kala Pharmaceuticals | Inveltys | $3,971 | 4 payments
|
| Amgen | None | $1,125 | 1 payment
|
| Dompe US | Oxervate | $153 | 1 payment
|
| Alcon Vision | Clareon | $99 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $85 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $65 | 1 payment
|
| BioTissue Holdings | Prokera | $29 | 1 payment
|
2021: $722
| Novartis Pharmaceuticals | Xiidra | $290 | 3 payments
|
| Alcon Vision | Acrysof Iq Panoptix | $226 | 2 payments
|
| Ocular Therapeutix | Dextenza | $162 | 1 payment
|
| Tissuetech | Prokera | $43 | 1 payment
|
2020: $1,715
| Seagen | None | $1,680 | 1 payment
|
| Genzyme | Fabrazyme | $35 | 1 payment
|
2019: $6,955
| Shire North American Group | Xiidra | $4,306 | 4 payments
|
| Kala Pharmaceuticals | Inveltys | $2,313 | 4 payments
|
| Alcon Vision | Centurion | $211 | 2 payments
|
| Novartis Pharmaceuticals | None | $125 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · Observational Study of Conjunctivitis in the Setting of Dupixent Treatment for Atopic Dermatitis · 2021 | Their institution | $15,898 |
| Regeneron Pharmaceuticals, Inc. · Observational Study of Conjunctivitis in the Setting of Dupixent Treatment for Atopic Dermatitis · 2022 | Their institution | $4,160 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1609903020
- Licence
- CA A54687California A54687: Current · expires 2027-07-31
- Trained
- University of Minnesota Medical School, 1994
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A546870
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-27
- NPI last updated
- 2024-04-04
- NPI record certified
- 2024-04-04
This is when the NPI record was last certified, not a medical board exam.